Last Price$184.9(2.1%)
Market Cap$33.7B
LTM PEG 1Y
0.4x
5Y avg
1.3x
Medical - Diagnostics & Research industry
median
0.1x
Stock quality & Intrinsic value
6/10
0.6% undervalued
IQVIA Holdings Inc. PEG 1Y
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PEG 1Y | 0.5x | 0.4x | 0.4x | 0.8x | 7.7x | 0.3x | 2.1x | 3.3x | 1.2x | 0.6x | 0.7x | 0.4x |
Overvalued or undervalued?
Check the intrinsic value for IQV
and see if it's the right time to invest.
IQVIA Holdings Inc. (IQV) PEG 1Y comparison analysis
General
LTM PEG 1Y
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
IQVIA Holdings Inc.IQV
0.4x
2.8%
2.4%
8.9%
Median Peer Set
1.3x
(0.5%)
(6.5%)
16.3%
IDEXX Laboratories, Inc.IDXX
14.5x
8.7%
25.2%
23.1%
Mettler-Toledo International Inc.MTD
8.0x
2.2%
12.7%
22.3%
Waters CorporationWAT
4.1x
(0.5%)
(7.9%)
21.7%
Natera, Inc.NTRA
1.5x
32.0%
(32.1%)
(40.2%)
Quest Diagnostics IncorporatedDGX
1.3x
(6.4%)
(6.5%)
9.2%
Agilent Technologies, Inc.A
1.1x
(4.7%)
5.0%
19.8%
Thermo Fisher Scientific Inc.TMO
0.8x
(4.6%)
(12.4%)
14.0%
Danaher CorporationDHR
0.7x
(0.1%)
(17.9%)
16.3%
Illumina, Inc.ILMN
0.1x
(2.9%)
4.6%
(28.0%)
IQV key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 3,924.0 0.0% | 4,327.7 10.3% | 4,865.5 12.4% | 5,099.5 4.8% | 5,460.0 7.1% | 5,737.6 5.1% | 6,878.0 19.9% | 9,739.0 41.6% | 10,412.0 6.9% | 11,088.0 6.5% | 11,359.0 2.4% | 13,874.0 22.1% | 14,410.0 3.9% | 14,984.0 4.0% | 15,405.0 2.8% |
| Cost of Goods Sold (COGS) | 2,804.8 | 3,185.8 | 3,632.6 | 3,762.6 | 3,978.3 | 4,136.8 | 4,750.0 | 6,301.0 | 6,746.0 | 7,300.0 | 7,500.0 | 9,233.0 | 9,382.0 | 9,745.0 | 10,030.0 |
% margin | 1,119.2 28.5% | 1,142.0 26.4% | 1,232.9 25.3% | 1,336.9 26.2% | 1,481.7 27.1% | 1,600.8 27.9% | 2,128.0 30.9% | 3,438.0 35.3% | 3,666.0 35.2% | 3,788.0 34.2% | 3,859.0 34.0% | 4,641.0 33.5% | 5,028.0 34.9% | 5,239.0 35.0% | 5,375.0 34.9% |
| Operating Expenses | 698.4 | 762.3 | 817.8 | 860.5 | 882.3 | 921.0 | 1,300.0 | 2,616.0 | 2,857.0 | 2,936.0 | 3,076.0 | 3,228.0 | 3,201.0 | 3,262.0 | 3,173.0 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 10.4 | 5.0 | 0.0 | 3.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, General & Administrative Expenses (SG&A) | 698.4 | 762.3 | 817.8 | 860.5 | 882.3 | 921.0 | 1,011.0 | 1,605.0 | 1,716.0 | 1,734.0 | 1,789.0 | 1,964.0 | 2,071.0 | 2,053.0 | 1,992.0 |
% margin | 395.0 10.1% | 345.3 8.0% | 396.4 8.1% | 462.3 9.1% | 590.4 10.8% | 646.6 11.3% | 642.0 9.3% | 719.0 7.4% | 741.0 7.1% | 777.0 7.0% | 731.0 6.4% | 1,393.0 10.0% | 1,799.0 12.5% | 1,977.0 13.2% | 2,202.0 14.3% |
| Interest Income | 3.8 | 3.9 | 3.1 | 3.9 | 3.4 | 4.3 | 4.0 | 7.0 | 8.0 | 9.0 | 6.0 | 6.0 | 13.0 | 36.0 | 47.0 |
| Interest Expense | 141.4 | 109.1 | 134.4 | 123.5 | 100.6 | 101.8 | 144.0 | 346.0 | 414.0 | 447.0 | 416.0 | 375.0 | 416.0 | 672.0 | 670.0 |
| Pre-tax Income | 241.7 | 184.7 | 267.4 | 323.1 | 502.2 | 539.0 | 479.0 | 331.0 | 328.0 | 352.0 | 373.0 | 1,128.0 | 1,363.0 | 1,459.0 | 1,669.0 |
% effective tax rate | 77.6 32.1% | 15.1 8.2% | 93.4 34.9% | 96.0 29.7% | 150.1 29.9% | 159.0 29.5% | 345.0 72.0% | (987.0) (298.2%) | 59.0 18.0% | 116.0 33.0% | 72.0 19.3% | 163.0 14.5% | 260.0 19.1% | 101.0 6.9% | 301.0 18.0% |
% margin | 160.6 4.1% | 241.8 5.6% | 177.5 3.6% | 226.6 4.4% | 356.4 6.5% | 387.2 6.7% | 115.0 1.7% | 1,309.0 13.4% | 259.0 2.5% | 191.0 1.7% | 279.0 2.5% | 966.0 7.0% | 1,091.0 7.6% | 1,358.0 9.1% | 1,373.0 8.9% |
| EPS | 1.28 | 1.93 | 1.42 | 1.83 | 2.78 | 3.15 | 0.77 | 6.01 | 1.27 | 0.98 | 1.46 | 5.05 | 5.82 | 7.39 | 7.57 |
| Diluted EPS | 1.26 | 1.90 | 1.39 | 1.77 | 2.72 | 3.08 | 0.76 | 5.88 | 1.24 | 0.96 | 1.43 | 4.95 | 5.72 | 7.29 | 7.49 |
% margin | 467.4 11.9% | 385.7 8.9% | 500.1 10.3% | 541.5 10.6% | 711.4 13.0% | 756.2 13.2% | 906.0 13.2% | 1,651.0 17.0% | 1,883.0 18.1% | 1,881.0 17.0% | 2,063.0 18.2% | 2,746.0 19.8% | 2,887.0 20.0% | 3,303.0 22.0% | 3,453.0 22.4% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is IQVIA Holdings Inc.'s PEG 1Y?
As of today, Microsoft Corp's last 12-month PEG 1Y is 0.4x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual PEG 1Y for IQVIA Holdings Inc. have been 0.8x over the past three years, and 1.4x over the past five years.
2) Is IQVIA Holdings Inc.'s PEG 1Y Good?
As of today, IQVIA Holdings Inc.'s PEG 1Y is 0.4x, which is higher than industry median of 0.1x. It indicates that IQVIA Holdings Inc.'s PEG 1Y is Bad.